Key result
Angiosarcoma of the breast accounts for 0.05% of primary breast malignancies and has a worse prognosis than other breast sarcomas, arising either de novo or after breast carcinoma treatment.
Key points are not available for this paper at this time.
Raises awareness of this rare aggressive tumor in post-treatment patients; leaves open optimal management strategies.
Angiosarcoma is a rare, highly malignant tumor of endothelial cells, and it accounts for 0.05% of all primary malignancies of the breast.1,2 Angiosarcoma has a worse prognosis than other sarcomas of the breast and can arise de novo (primary angiosarcoma) or after treatment for breast carcinoma (secondary).3–5
No takes yet. Share an insight, caveat, or question.
Weinfurtner et al. (2016) studied this question. Angiosarcoma of the breast accounts for 0.05% of primary breast malignancies and has a worse prognosis than other breast sarcomas, arising either de novo or after breast carcinoma treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: